Get the Stockscreener App
0.1646
2.67%
-0.0039
Iterum Therapeutics Plc stock is traded at $0.1646, with a volume of 1.35M.
It is down -2.67% in the last 24 hours and down -42.50% over the past month.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
See More
Previous Close:
$0.1685
Open:
$0.169
24h Volume:
1.35M
Relative Volume:
1.56
Market Cap:
$8.73M
Revenue:
-
Net Income/Loss:
$-26.96M
P/E Ratio:
-0.2197
EPS:
-0.7492
Net Cash Flow:
$-19.62M
1W Performance:
-30.51%
1M Performance:
-42.50%
6M Performance:
-75.82%
1Y Performance:
-87.94%
1-Day Range:
$0.154
$0.1721
1-Week Range:
$0.1357
$0.30
52-Week Range:
$0.1357
$1.50
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Name
Iterum Therapeutics Plc
Sector
Industry
Phone
(872) 225-6077
Address
3 DUBLIN LANDINGS, DUBLIN 1
Compare ITRM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.1638 | 8.98M | 0 | -26.96M | -19.62M | -0.7492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-21 | Upgrade | Gabelli & Co | Sell → Hold |
| Mar-15-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-21-20 | Downgrade | Gabelli & Co | Buy → Sell |
| Dec-11-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Iterum Therapeutics Plc Stock (ITRM) Latest News
Iterum Therapeutics (ITRM) Downgraded Amid Delisting Concerns - GuruFocus
Iterum Therapeutics Appeals Nasdaq Delisting, Explores Strategic Alternatives - TipRanks
Iterum Therapeutics requests Nasdaq hearing after delisting notice, may face wind-down or strategic sale - TradingView
Iterum Therapeutics requests Nasdaq hearing after delisting notice - Investing.com
Iterum Therapeutics (ITRM) faces Nasdaq delisting and flags possible bankruptcy - Stock Titan
Returns Recap: What drives First Majestic Silver Corps stock priceCPI Data & Precise Buy Zone Tips - baoquankhu1.vn
Iterum Therapeutics Faces Nasdaq Delisting, Weighs Strategic Options - TipRanks
Iterum Therapeutics Received Notice of Delisting - TradingView
Nasdaq delisting and wind-down risk at Iterum Therapeutics (NASDAQ: ITRM) - Stock Titan
ITRM Should I Buy - Intellectia AI
ITRM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Smart Money: Does Iterum Therapeutics plc outperform in volatile marketsJuly 2025 Patterns & AI Powered Trade Plan Recommendations - baoquankhu1.vn
What dividend growth rate does Iterum Therapeutics plc offerJuly 2025 Opening Moves & Smart Investment Allocation Tips - mfd.ru
Iterum Therapeutics PLC expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Iterum Therapeutics Shareholders Reject Key Capital Proposals - TipRanks
Iterum Therapeutics (NASDAQ: ITRM) flags going‑concern risk after failed capital votes - Stock Titan
Can Iterum Therapeutics plc sustain its profitabilityEarnings Growth Report & Step-by-Step Trade Execution Guides - mfd.ru
Decliners Report: What dividend growth rate does Iterum Therapeutics plc offer2025 Key Highlights & High Conviction Trade Alerts - baoquankhu1.vn
Iterum Therapeutics expands Medicare Part D access for ORLYNVAH By Investing.com - Investing.com Australia
Iterum Therapeutics expands Medicare Part D access for ORLYNVAH - Investing.com South Africa
Iterum Therapeutics Provides Business Update - Intellectia AI
Iterum Therapeutics Announces Expanded Market Access and Patent Protection for ORLYNVAH™ - Quiver Quantitative
Iterum Therapeutics provides business update - marketscreener.com
Published on: 2026-02-12 20:05:19 - baoquankhu1.vn
Is Iterum Therapeutics plc’s ROIC above industry averageMarket Weekly Review & Risk Controlled Stock Pick Alerts - mfd.ru
Is Iterum Therapeutics plc stock forming a triangle patternDividend Hike & Low Volatility Stock Recommendations - mfd.ru
Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Friday - Defense World
Investment Review: What dividend growth rate does CTNT offerEarnings Trend Report & Low Risk High Reward Ideas - baoquankhu1.vn
Gap Down: Is UPSD stock a good pick for beginners2025 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
Fed Meeting: How correlated is W R Berkley Corporation to the S P500July 2025 Gainers & Verified Swing Trading Watchlist - baoquankhu1.vn
ITRM Stock Price, Forecast & Analysis | ITERUM THERAPEUTICS PLC (NASDAQ:ITRM) - Chartmill
Portfolio Recap: Is Iterum Therapeutics plc stock risky to hold now2025 Earnings Impact & Community Trade Idea Sharing Platform - baoquankhu1.vn
Weekly Earnings: How does Hovnanian Enterprises Inc compare to its peersRate Cut & Real-Time Price Movement Reports - baoquankhu1.vn
Activity Recap: What are the future prospects of Iterum Therapeutics plcMarket Sentiment Report & Fast Gaining Stock Reports - baoquankhu1.vn
Patterns Watch: Is Iterum Therapeutics plc stock a safe haven assetLayoff News & Low Risk Entry Point Tips - Bộ Nội Vụ
Will Iterum Therapeutics plc stock benefit from green energy trendsJuly 2025 Earnings & Daily Profit Focused Screening - Улправда
Is Iterum Therapeutics plc stock overvalued by current metricsProfit Target & High Return Trade Opportunity Guides - ulpravda.ru
Will Iterum Therapeutics plc stock benefit from sector rotationInflation Watch & Safe Capital Growth Stock Tips - Улправда
Can Iterum Therapeutics plc stock deliver surprise earnings beatWeekly Trade Report & Expert Curated Trade Setup Alerts - Улправда
Why Iterum Therapeutics plc stock remains a top recommendationStock Buyback Updates & Market Monitoring and Alerts - Улправда
Iterum Therapeutics expands market access for ORLYNVAH antibiotic - Investing.com
New antibiotic ORLYNVAH could reach 34M+ people pending FDA feedback - Stock Titan
Analyzing Iterum Therapeutics (NASDAQ:ITRM) & Savara (NASDAQ:SVRA) - Defense World
Why hedge funds are buying Iterum Therapeutics plc stockWeekly Trade Analysis & Capital Efficient Trade Techniques - Улправда
Iterum Therapeutics secures major PBM agreement for antibiotic By Investing.com - Investing.com Nigeria
Iterum Therapeutics (ITRM) Secures Key PBM Agreement and Expands Patent Portfolio - GuruFocus
Iterum Therapeutics secures major PBM agreement for antibiotic - Investing.com
New PBM deal could open ORLYNVAH access to 40M more people in 2026 - Stock Titan
Iterum Therapeutics faces Nasdaq listing compliance challenge - MSN
Iterum Therapeutics receives Nasdaq notice on listing compliance By Investing.com - Investing.com India
Iterum Therapeutics plc Stock Analysis and ForecastEarnings Forecast Updates & Fast Profit Stock Ideas - earlytimes.in
Iterum Therapeutics Plc Stock (ITRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):